瑞可達(688800.SH):公司人形機器人產品經過前期的研發,現已開始小批量供貨
格隆匯8月4日丨瑞可達(688800.SH)公佈,近期有媒體關注到公司有應用於人形機器人的產品,已小批量供貨中。截至目前,公司人形機器人產品經過前期的研發,現已開始小批量供貨,預計2025年該業務板塊的銷售收入約1000萬,佔2024年營業收入比例爲0.41%,由於目前尚處於產業初期,在公司的實際業績中佔比較小,該業務板塊當年實現的銷售收入尚存在不確定性,敬請投資者謹慎決策,理性對待市場熱點概念,注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.